BRPI0011407B8 - molécula de ácido nucléico quimérica, polipeptídeo de fusão, vetor de expressão, sistema de vetor hospedeiro, e, métodos de produzir um polipeptídeo de fusão - Google Patents

molécula de ácido nucléico quimérica, polipeptídeo de fusão, vetor de expressão, sistema de vetor hospedeiro, e, métodos de produzir um polipeptídeo de fusão

Info

Publication number
BRPI0011407B8
BRPI0011407B8 BRPI0011407A BRPI0011407A BRPI0011407B8 BR PI0011407 B8 BRPI0011407 B8 BR PI0011407B8 BR PI0011407 A BRPI0011407 A BR PI0011407A BR PI0011407 A BRPI0011407 A BR PI0011407A BR PI0011407 B8 BRPI0011407 B8 BR PI0011407B8
Authority
BR
Brazil
Prior art keywords
fusion polypeptide
nucleic acid
producing
methods
acid molecule
Prior art date
Application number
BRPI0011407A
Other languages
English (en)
Portuguese (pt)
Inventor
D Yancopoulos George
J Papadopoulos Nicholas
Davis Samuel
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22480568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0011407(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BRPI0011407B1 publication Critical patent/BRPI0011407B1/pt
Publication of BRPI0011407B8 publication Critical patent/BRPI0011407B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
BRPI0011407A 1999-06-08 2000-05-23 molécula de ácido nucléico quimérica, polipeptídeo de fusão, vetor de expressão, sistema de vetor hospedeiro, e, métodos de produzir um polipeptídeo de fusão BRPI0011407B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13813399P 1999-06-08 1999-06-08
PCT/US2000/014142 WO2000075319A1 (en) 1999-06-08 2000-05-23 Modified chimeric polypeptides with improved pharmacokinetic properties

Publications (2)

Publication Number Publication Date
BRPI0011407B1 BRPI0011407B1 (pt) 2018-09-25
BRPI0011407B8 true BRPI0011407B8 (pt) 2021-05-25

Family

ID=22480568

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0011407-3A BR0011407A (pt) 1999-06-08 2000-05-23 Molécula de ácido nucléico isolada, polipeptìdeo de fusão, composição, vetor, sistema de vetor, sistema de vetor hospedeiro, métodos de produzir um polipeptìdeo de fusão.
BRPI0011407A BRPI0011407B8 (pt) 1999-06-08 2000-05-23 molécula de ácido nucléico quimérica, polipeptídeo de fusão, vetor de expressão, sistema de vetor hospedeiro, e, métodos de produzir um polipeptídeo de fusão

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR0011407-3A BR0011407A (pt) 1999-06-08 2000-05-23 Molécula de ácido nucléico isolada, polipeptìdeo de fusão, composição, vetor, sistema de vetor, sistema de vetor hospedeiro, métodos de produzir um polipeptìdeo de fusão.

Country Status (32)

Country Link
EP (2) EP1544299B1 (https=)
JP (2) JP4723140B2 (https=)
KR (1) KR100659477B1 (https=)
CN (3) CN101433715B (https=)
AT (2) ATE417928T1 (https=)
AU (2) AU779303B2 (https=)
BE (1) BE2013C029I2 (https=)
BR (2) BR0011407A (https=)
CA (1) CA2376379C (https=)
CY (2) CY1108883T1 (https=)
CZ (2) CZ303656B6 (https=)
DE (2) DE60041159D1 (https=)
DK (2) DK1183353T3 (https=)
ES (2) ES2237429T3 (https=)
FR (1) FR13C0028I2 (https=)
HR (1) HRP20010908B1 (https=)
HU (3) HU229156B1 (https=)
IL (3) IL146890A0 (https=)
LT (1) LTC1183353I2 (https=)
LU (1) LU92195I2 (https=)
ME (2) MEP3208A (https=)
MX (1) MXPA01012630A (https=)
NO (4) NO330775B1 (https=)
NZ (1) NZ515913A (https=)
PL (1) PL208247B1 (https=)
PT (2) PT1183353E (https=)
RS (1) RS50073B (https=)
RU (1) RU2265661C2 (https=)
SK (1) SK287332B6 (https=)
UA (1) UA74146C2 (https=)
WO (1) WO2000075319A1 (https=)
ZA (1) ZA200110068B (https=)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710174B2 (en) 2001-09-13 2004-03-23 Isis Pharmaceuticals, Inc. Antisense inhibition of vascular endothelial growth factor receptor-1 expression
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
CA2435503C (en) 2001-01-19 2011-02-22 Ludwig Institute For Cancer Research Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
US6734017B2 (en) 2001-09-28 2004-05-11 Isis Pharmaceuticals, Inc. Antisense modulation of vascular endothelial growth factor receptor-2 expression
US8183350B2 (en) 2002-05-04 2012-05-22 Acorda Therapeutics, Inc. Compositions and methods for promoting neuronal outgrowth
WO2004087206A2 (en) 2003-03-28 2004-10-14 Regeneron Pharmaceuticals, Inc. Methods of treating diabetes by blocking vegf-mediated activity
EP3211084B1 (en) 2003-05-16 2019-03-27 Acorda Therapeutics, Inc. Proteoglycan degrading mutants for treatment of cns
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
AU2004247025B8 (en) * 2003-05-16 2011-06-30 Acorda Therapeutics, Inc. Fusion proteins for the treatment of CNS
CA2519835A1 (en) * 2003-05-28 2004-12-09 Regeneron Pharmaceuticals, Inc. Method of treating corneal transplant rejection
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
WO2004110490A2 (en) * 2003-06-06 2004-12-23 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitors for tumor regression
US7399612B2 (en) 2003-06-30 2008-07-15 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
AR046510A1 (es) * 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
WO2005016369A1 (en) * 2003-08-06 2005-02-24 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist in combination with radiation therapy
MXPA06013345A (es) 2004-05-18 2008-10-31 Acorda Therapeutics Inc Metodos para purificar condrointinasa y sus formulaciones estables.
EP1767546B1 (en) 2004-06-08 2012-03-07 Chengdu Kanghong Biotechnologies Co., Ltd. Angiogenesis-inhibiting chimeric protein and the use
CA2567686A1 (en) 2004-06-10 2005-12-29 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitors for the treatment of human cancer
MXPA06014689A (es) * 2004-06-18 2008-03-11 Regeneron Pharma Inhibidores del vegf para el tratamiento de efusion pleural maligna.
AU2005267741A1 (en) * 2004-07-30 2006-02-09 Regeneron Pharmaceuticals, Inc. Methods of treating type I diabetes by blocking VEGF-mediated activity
PT2229956E (pt) * 2004-09-13 2013-07-31 Genzyme Corp Contruções multiméricas
FR2878749B1 (fr) * 2004-12-03 2007-12-21 Aventis Pharma Sa Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
US7303748B2 (en) 2005-02-02 2007-12-04 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a VEGF inhibitor
ES2633574T3 (es) 2005-03-25 2017-09-22 Regeneron Pharmaceuticals, Inc. Formulaciones de antagonistas de VEGF
JP5189985B2 (ja) 2005-09-26 2013-04-24 アコーダ セラピューティクス、インク． コンドロイチナーゼａｂｃｉ変異体を用いた組成物およびその使用方法
CA2630839C (en) † 2005-12-16 2017-01-17 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with dll4 antagonists
FR2895258B1 (fr) 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
CN100502945C (zh) * 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
DK2066694T3 (en) 2006-09-29 2016-02-08 Oncomed Pharm Inc Compositions and Methods for Diagnosing and Treating Cancer
CA3009034C (en) 2006-10-10 2020-08-18 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
FR2918279B1 (fr) * 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
CN101575379B (zh) * 2008-05-09 2012-05-30 上海抗体药物国家工程研究中心有限公司 可溶性vegfr双功能融合受体、其制备方法及用途
BRPI0921469B1 (pt) 2008-11-03 2022-01-18 Molecular Partners Ag Proteínas de ligação que inibem a interação com o receptor de vegf-a, composição farmacêutica
CN101838329A (zh) * 2009-03-18 2010-09-22 嘉和生物药业有限公司 抗血管新生融合蛋白
HUE029661T2 (en) 2009-10-16 2017-03-28 Oncomed Pharm Inc A therapeutic combination and use of DLL4 antagonist antibodies and antihypertensive agents
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
EP3327032A1 (en) 2010-08-06 2018-05-30 Genzyme Corporation Vegf antagonist compositions and uses thereof
WO2012093704A1 (ja) * 2011-01-07 2012-07-12 中外製薬株式会社 抗体の物性を改善させる方法
KR20190049934A (ko) 2011-01-13 2019-05-09 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
KR101397088B1 (ko) 2011-06-10 2014-05-19 강원대학교산학협력단 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물
JO3370B1 (ar) * 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
ES2651521T3 (es) * 2011-12-01 2018-01-26 Innovent Biologics, Inc. Inhibidores proteicos de las rutas del complemento y de VEGF y métodos de uso de los mismos
CN103304668B (zh) * 2012-03-12 2015-10-28 江苏健德生物药业有限公司 Ultra-VEGF-trap免疫融合蛋白、其制备方法及其应用
ES2753135T3 (es) 2012-05-07 2020-04-07 Allergan Inc Método de tratamiento de DMAE en pacientes resistentes a terapia anti-VEGF
WO2014006113A1 (en) 2012-07-03 2014-01-09 Sanofi Method of treating cancer by effective amounts of aflibercept
AR093445A1 (es) 2012-11-14 2015-06-10 Regeneron Pharma Metodos para tratar el cancer de ovario con antagonistas de dll4
RS60026B1 (sr) 2013-02-18 2020-04-30 Vegenics Pty Ltd Molekuli koji vezuju ligande i njihove upotrebe
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
CN104193828B (zh) * 2013-09-12 2017-04-05 北京韩美药品有限公司 同时阻断her2和vegfr信号通路的重组融合蛋白
PT3065761T (pt) 2013-11-05 2020-02-21 Allergan Inc Método de tratamento de condições oculares com um darpin anti-vegf
CN106456757A (zh) 2014-05-12 2017-02-22 福尔密孔股份公司 含有vegf拮抗剂的预填充塑料注射器
EA035674B1 (ru) 2014-07-18 2020-07-24 Санофи Способ определения того, является ли пациент, предположительно страдающий от рака, кандидатом для терапии афлиберцептом
JP2016036322A (ja) * 2014-08-11 2016-03-22 日本化薬株式会社 血管新生因子と結合するキメラタンパク質
CN114306575A (zh) 2014-12-11 2022-04-12 拜耳医药保健有限责任公司 具有小的活动性脉络膜新生血管病变的年龄相关性黄斑变性的治疗
GB201503453D0 (en) 2015-03-01 2015-04-15 Jain Arjun Endothelin-1"sponge"
TWI870789B (zh) 2015-08-04 2025-01-21 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
WO2017046140A1 (en) 2015-09-18 2017-03-23 Bayer Pharma Aktiengesellschaft Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
KR101936049B1 (ko) 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
WO2017065559A1 (ko) 2015-10-15 2017-04-20 (주)알테오젠 Igg fc 도메인을 가지는 융합 단백질의 생산방법
CN108290004A (zh) 2015-11-18 2018-07-17 福尔密孔股份公司 含有vegf拮抗剂的预填充塑料注射器
CA3005132A1 (en) 2015-11-18 2017-05-26 Sio2 Medical Products, Inc. Coated syringe for ophthalmic formulations containing a vegf antagonist
WO2018218013A2 (en) 2017-05-24 2018-11-29 Sio2 Medical Products, Inc. Sterilizable pharmaceutical package for ophthalmic formulations
EP3377100B1 (en) 2015-11-18 2025-02-26 Formycon AG Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist
WO2017084616A1 (en) * 2015-11-19 2017-05-26 Zhuhai Tairuishang Biopharm Ltd. Methods and compositions for binding vegf
WO2017096031A1 (en) 2015-12-03 2017-06-08 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf
US10576128B2 (en) 2016-01-26 2020-03-03 Formycon Ag Liquid formulation of a VEGF antagonist
JPWO2018070390A1 (ja) 2016-10-12 2019-08-22 第一三共株式会社 抗ｒｏｂｏ４抗体と他剤を含む組成物
JP7116059B2 (ja) 2016-11-21 2022-08-09 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド アフリベルセプト製剤及びその使用
EP3630043A1 (en) 2017-05-24 2020-04-08 Formycon AG Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
WO2018215580A1 (en) 2017-05-24 2018-11-29 Formycon Ag Method for sterilizing prefilled plastic syringes containing a vegf antagonist
TW201904610A (zh) 2017-06-14 2019-02-01 德商拜耳製藥公司 用於治療新生血管型青光眼之非抗體vegf拮抗劑
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
EP3668985B1 (en) 2017-08-17 2021-06-16 Just-Evotec Biologics, Inc. Method of purifying glycosylated protein from host cell galectins and other contaminants
MY202872A (en) 2017-11-20 2024-05-28 Just Evotec Biologics Inc Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
CN111770999A (zh) * 2017-11-27 2020-10-13 4D分子治疗有限公司 腺相关病毒变体衣壳和用于抑制血管生成的应用
HUE059827T2 (hu) * 2017-11-30 2023-01-28 Regeneron Pharma VEGF-antagonista alkalmazása angiogén szembetegségek kezelésére
IL319165A (en) * 2017-12-13 2025-04-01 Regeneron Pharma Apparatus and methods for managing support of a chromatography column substrate and related methods
WO2019124946A1 (ko) 2017-12-22 2019-06-27 삼성바이오에피스 주식회사 Vegf 길항제를 포함하는 액상 조성물
AU2019212622B2 (en) 2018-01-26 2024-05-23 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
EP3758737A4 (en) 2018-03-02 2022-10-12 Kodiak Sciences Inc. IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
DK4364724T3 (da) 2018-05-10 2025-12-22 Regeneron Pharma Formuleringer med høj koncentration af VEGF-receptorfusionsprotein
TW202016125A (zh) * 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
CN111378044B (zh) 2018-12-28 2022-07-15 长春金赛药业有限责任公司 抗体融合蛋白、制备方法及其应用
WO2020229584A1 (en) 2019-05-16 2020-11-19 Formycon Ag Method for reducing methionine oxidation in recombinant proteins
TWI904098B (zh) 2019-09-03 2025-11-11 美商安進公司 用於藥物遞送之注入裝置及用於注入裝置之包裝物
MX2022002980A (es) 2019-09-16 2022-04-06 Amgen Inc Metodo para la esterilizacion externa de un dispositivo de suministro de farmacos.
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
BR112022010113A2 (pt) 2019-11-25 2022-09-06 Univ California Inibidores de vegf de longa ação para neovascularização intraocular
SG11202110968VA (en) 2019-12-06 2021-10-28 Regeneron Pharma Anti-vegf protein compositions and methods for producing the same
IL293286A (en) 2019-12-06 2022-07-01 Regeneron Pharma vegf mini-traps and methods of using them
WO2021173603A1 (en) 2020-02-24 2021-09-02 Amgen Inc. Containers and systems for use during external sterilization of drug delivery devices
AU2021268026A1 (en) 2020-05-08 2023-01-19 Regeneron Pharmaceuticals, Inc. VEGF traps and mini-traps and methods for treating ocular disorders and cancer
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
EP4145456A1 (en) 2021-09-06 2023-03-08 Bayer AG Prediction of a change related to a macular fluid
EP4438629A1 (en) 2021-11-24 2024-10-02 Suzhou Light Ferry Biomed. Co., Ltd Multispecific ligand binding molecule and application thereof
CN119677771A (zh) 2022-08-02 2025-03-21 帕诺洛斯生物科技有限公司 经修饰的融合蛋白及其用途
TW202412840A (zh) 2022-09-16 2024-04-01 大陸商齊魯製藥有限公司 一種穩定的高濃度自緩衝藥物組合物
AU2024322540A1 (en) 2023-08-04 2026-03-05 Panolos Bioscience, Inc. Conjugate of modified fusion protein and scfv, and use thereof
WO2025213011A1 (en) 2024-04-05 2025-10-09 Amgen Inc. Method of assessing stopper movement in a drug delivery device

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506466D0 (en) * 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production

Also Published As

Publication number Publication date
KR20020019070A (ko) 2002-03-09
CZ303656B6 (cs) 2013-01-30
NO332559B1 (no) 2012-10-29
RS50073B (sr) 2009-01-22
BE2013C029I2 (https=) 2019-03-06
IL146890A (en) 2008-07-08
ME00024B (me) 2010-02-10
KR100659477B1 (ko) 2006-12-20
CA2376379A1 (en) 2000-12-14
JP5273746B2 (ja) 2013-08-28
DE60019415D1 (de) 2005-05-19
LU92195I2 (fr) 2013-07-15
HUP0201515A3 (en) 2004-12-28
ZA200110068B (en) 2002-12-06
BRPI0011407B1 (pt) 2018-09-25
PL352246A1 (en) 2003-08-11
PT1183353E (pt) 2005-06-30
ATE417928T1 (de) 2009-01-15
WO2000075319A1 (en) 2000-12-14
HRP20010908B1 (en) 2006-05-31
SK287332B6 (sk) 2010-07-07
RU2265661C2 (ru) 2005-12-10
JP4723140B2 (ja) 2011-07-13
EP1544299B1 (en) 2008-12-17
FR13C0028I1 (fr) 2013-06-14
CY1108883T1 (el) 2014-07-02
NO2022060I1 (no) 2022-12-21
JP2011024595A (ja) 2011-02-10
EP1544299A1 (en) 2005-06-22
HUP0201515A2 (en) 2002-08-28
IL146890A0 (en) 2002-08-14
BR0011407A (pt) 2002-04-02
DE60019415T2 (de) 2006-03-09
CN1369009A (zh) 2002-09-11
HK1185798A1 (en) 2014-02-28
HU230159B1 (hu) 2015-09-28
MXPA01012630A (es) 2002-07-22
HUS1300052I1 (hu) 2016-08-29
EP1183353A1 (en) 2002-03-06
FR13C0028I2 (fr) 2014-05-16
AU5040400A (en) 2000-12-28
AU2005201365A1 (en) 2005-04-28
LTPA2013009I1 (lt) 2013-06-25
NO20100656L (no) 2002-02-08
ATE293164T1 (de) 2005-04-15
CY2013019I1 (el) 2015-11-04
MEP3208A (xx) 2010-02-10
AU779303B2 (en) 2005-01-13
NO2013010I2 (no) 2013-05-15
HU229156B1 (en) 2013-09-30
SK17522001A3 (sk) 2003-04-01
CN101433715A (zh) 2009-05-20
JP2003501089A (ja) 2003-01-14
DE60041159D1 (de) 2009-01-29
YU86901A (sh) 2004-05-12
CY2013019I2 (el) 2015-11-04
HRP20010908A2 (en) 2005-04-30
ES2237429T3 (es) 2005-08-01
CN100523187C (zh) 2009-08-05
CZ302689B6 (cs) 2011-09-07
NO20016036D0 (no) 2001-12-10
IL190234A0 (en) 2008-11-03
NO330775B1 (no) 2011-07-11
PL208247B1 (pl) 2011-04-29
AU2005201365B2 (en) 2007-08-09
CZ20014387A3 (cs) 2002-10-16
NO2013010I1 (no) 2013-06-17
LTC1183353I2 (lt) 2023-02-27
CN103349781A (zh) 2013-10-16
DK1544299T3 (da) 2009-03-23
ES2319305T3 (es) 2009-05-06
DK1183353T3 (da) 2005-08-08
CN103349781B (zh) 2015-04-01
HK1043388A1 (en) 2002-09-13
NZ515913A (en) 2004-01-30
NO20016036L (no) 2002-02-08
HK1132653A1 (en) 2010-03-05
CA2376379C (en) 2007-08-07
UA74146C2 (uk) 2005-11-15
PT1544299E (pt) 2009-03-18
EP1183353B1 (en) 2005-04-13
CN101433715B (zh) 2013-04-17

Similar Documents

Publication Publication Date Title
BRPI0011407B8 (pt) molécula de ácido nucléico quimérica, polipeptídeo de fusão, vetor de expressão, sistema de vetor hospedeiro, e, métodos de produzir um polipeptídeo de fusão
ATE352626T1 (de) Polypeptide mit galaktoseoxidaseaktivität und dafür kodierende nukleisäuren
BR0007414A (pt) Expressão e exportação de proteìnas antiobesidade como proteìnas de fusão fc
BR0009392A (pt) Polipeptìdeo, sequência de ácido nucleico, vetor de expressão recombinante, célula hospedeira recombinante, métodos para produzir uma sequência de ácido nucleico mutante e para produzir um polipeptìdeo, mutante de um polipeptìdeo com atividade de alafa-amilase, e, uso do polipeptìdeo ou variante
ATE286907T1 (de) Cytokinin-designiertes lerk-5
BR9814404A (pt) " clonagem de expressão em fungos filamentosos "
BR0113921A (pt) ácidos nucléicos e polipeptìdeos receptores
AU9174398A (en) Peptides
BR0009393A (pt) Polipeptìdeo, sequência de ácido nucleico isolada, construção de ácido nucleico, vetor de expressão recombinante, célula hospedeira recombinante, método para a produção do polipeptìdeo, uso de um polipeptìdeo, e, composição detergente
BR0214350A (pt) Sequências de ácido nucleico e aminoácido de adenovìrus de sìmio, vetores contendo as mesmas e métodos de uso
DE69634640D1 (de) Mutierte alpha-amylase enzyme mit erhöhter stabilität
BR9911549A (pt) Processo de produção de fitase em levedura
DE69836092D1 (de) Rekombinatorisches klonieren unter verwendung von nukleinsaüren mit rekombinationsstellen
AU2001291687A1 (en) Polyammonium-polysiloxane compounds, methods for the production and use thereof
AU6542598A (en) Site protected protein modification
AR007737A1 (es) Un derivado de un peptido soluble, un procedimiento para su preparacion, una porcion polipeptidica del mismo, un polimero de adn, un vector de expresionreplicable, una celula huesped, un elemento peptidico modificado que se une a la membrana, una composicion farmaceutica que comprende dicho derivado y el uso
BR0208874A (pt) Proteìnas superficiais de streptococcus pyogenes
DK1007537T3 (da) Receptor-protein med betegnelsen 2F1
IL148785A0 (en) Vectors and methods for recombinant protein expression
DE69511399D1 (de) Isolierte, von mage-3 abgeleitete peptide, welche mit hla-a2 molekülen komplexieren
BR9101137A (pt) Metodo para a preparacao de um vetor hibrido,processo para a preparacao de uma molecula de dna,metodo para a preparacao de um hospedeiro e para a preparacao de um polipeptidio e metodo para a preparacao de psm puro
FI962268L (fi) Homologinen, rekombinanttinen vasta-aineilmentämisjärjestelmä rottien tai hiirien soluille
DE69834565D1 (de) Schnell erzeugung von stabilen säugertier-zellinien mit gewinnung eines hohen gehalts von recombinanten proteine
WO2000069884A3 (en) Compositions isolated from skin cells and methods for their use
BR0115121A (pt) Compostos n-((1,2,4)triazoloazinil)tiofenossulfonamida como herbicidas

Legal Events

Date Code Title Description
B19A Notification of judicial decision: notification of judicial decision

Free format text: PROCESSO INPI NO 52402.007729/2023-82 NUP: 00424.114254/2023-28 (REF. 1029948-81.2023.4.01.3400) POLO ATIVO: REGENERON PHARMACEUTICALS, INC POLO PASSIVO:INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL ? INPI SENTENCA: DEVERA O INPI PUBLICAR A INFORMACAO DE QUE O PRAZO DE VIGENCIA DA PATENTE OBJETO DESTA ACAO ESTA SUB JUDICE, TANTO NA REVISTA DE PROPRIEDADE INDUSTRIAL, QUANTO NO STATUS DA RESPECTIVA PATENTE NO SITIO DO INPI NA INTERNET (ART. 59, INCISO II, 60 E 226 DA LPI).

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI NO 52402.007729/2023-82 ORIGEM: 7A VARA FEDERAL CIVEL DA SJDF (TRF1) PROCESSO NO: 1029948-81.2023.4.01.3400 ACAO PELO PROCEDIMENTO COMUM AUTOR: REGENERON PHARMACEUTICALS, INC. REU(S): INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL